Antiangiogenesis drugs target specific cancers, mechanisms.
Randal
J
J
D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001632:Bibenzyls / Q000627:therapeutic use; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000201:enzymology; D010446:Peptide Fragments / Q000627:therapeutic use*; D010958:Plasminogen / Q000627:therapeutic use*; D013267:Stilbenes
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001632:Bibenzyls; D061965:Matrix Metalloproteinase Inhibitors; D010446:Peptide Fragments; D013267:Stilbenes; C040105:combretastatin; D043168:Angiostatins; D010958:Plasminogen